



*HCC-UK is supported by sponsors including pharmaceutical companies. Pharmaceutical companies have solely provided financial sponsorship, with no input into the arrangements or agenda of the meeting, except where indicated. A full list of sponsors can be found at the bottom of the agenda*

## HCC-UK Programme

**THURSDAY 19<sup>TH</sup> MARCH 2026**

11:55-12:00	<b>Welcome and Introduction</b> <b>Chair: Matthew Hoare</b>	
12:00-12:15	Elucidating the role of mitochondrial nucleotide metabolism in hepatocellular carcinoma <b>Speaker:</b> Sara Gohar, CRUK Scotland Institute	
12:15-12:30	Developing a preclinical mouse model to study image-guided stereotactic ablative radiotherapy and systemic treatment <b>Speaker:</b> Stephanie May, CRUK Scotland Institute	
12:30-13:00	Genetic background sets the trajectory of liver cancer evolution <b>Speaker:</b> Dr Sarah Aitken, Yale School of Medicine (Virtual)	
13:00-14.00	<b>Lunch – Posters &amp; Exhibition</b>	
<b>Session 2- Microenvironment in HCC</b> <b>Chair: Shish Shetty</b>		
14.00-14.30	Roles of hepatic metabolism in anti-tumour-immunity <b>Speaker:</b> Prof Dimitrios Anastasiou, Francis Crick Institute	
14:30-14:45	Liver-specific microbiota and microbial-derived metabolites rewire metabolic and structural phenotypes in hepatocellular carcinoma (HCC) <b>Speaker:</b> Niyati Raj, Roger Williams Institute of Liver Studies	
14:45-15.00	Spatial-temporal analysis of human-correlated mouse models reveals steatosis-linked evolutionary heterogeneity of hepatocellular carcinoma <b>Speaker:</b> Fiona Chalmers, CRUK Scotland Institute	
15:00-15:30	Tissue-resident memory CD8 T cells: master deciphers of their environment" <b>Speaker:</b> Dr Laura Pallett, University College London	
15:30-16.00	<b>Refreshments &amp; Exhibition</b>	



*HCC-UK is supported by sponsors including pharmaceutical companies. Pharmaceutical companies have solely provided financial sponsorship, with no input into the arrangements or agenda of the meeting, except where indicated. A full list of sponsors can be found at the bottom of the agenda*

### Session 3 - Microenvironment in HCC

Chair: Tom Bird

16:00–16:30	From Vector Design to Scalable Manufacturing: Optimization of Cytokine-Armored GPC3 CAR-NK Cells for Enhanced Anti-HCC Activity <b>Speaker:</b> Dr Ester Badami, RiMED Foundation, Palermo	
16:30–16:45	Spatial multi-omic profiling reveals metal-metabolic microenvironments that program regulatory T cell function in hepatocellular carcinoma <b>Speaker:</b> Leonard Bellersheim, King's College London	
16:45-17:00	Highly cytotoxic gamma delta T cells combined with locoregional drug delivery demonstrates effective treatment for hepatocellular carcinoma <b>Speaker:</b> Nekisa Zakeri, University of Birmingham	
17:00-17:30	Un-hijacking the immune system to improve response to IO in HCC <b>Speaker:</b> Prof Tom Marron, Mount Sinai School of Medicine, NY (Virtual)	
19.30-11.00	<b>HCC-UK Dinner</b>	

## State of the Art HCC management in 2026

FRIDAY 20<sup>TH</sup> MARCH 2026

### Session 1 - Surgical treatment

Chair: Stephanos Pericleous and David Wallace

08:15	<i>Registration</i>	
08.30 -09.00	<b>AstraZeneca Sponsored Symposium</b>	
09:00-09:10	<b>Welcome</b> <i>Speaker:</i> Abid Suddle	
09:10-09:35	Robotic liver resections <b>Speaker:</b> <i>Mr Gianluca Rompianesi - Virtual</i>	



**HCC-UK is supported by sponsors including pharmaceutical companies. Pharmaceutical companies have solely provided financial sponsorship, with no input into the arrangements or agenda of the meeting, except where indicated. A full list of sponsors can be found at the bottom of the agenda**

09.35-10.10	<p><b>Debate:</b> Criteria for Liver Transplant should be extended in the era of LDLT</p> <p><b>Pro</b> – Ms Miriam Cortes <b>Con</b> – Rohit Gaurav</p>	
10:10-10:40	<p><b>Best of Abstracts – Chair – Dr Nekisa Zakeri</b></p> <p>Selective Internal Radiation Therapy (SIRT) – a UK Multicentre Audit on Treatment Practice <b>Speaker:</b> David Barnes, New castle University</p> <p>Combining locoregional therapies with immune checkpoint inhibitors may improve outcomes for patients with advanced hepatocellular carcinoma <b>Speaker:</b> Mzamo Mbelle, Kings College Hospital</p>	
10.40-11:10	<i>Refreshments and Exhibition</i>	
<p><b>Session 2: Joint session with BSIR IO</b> <b>Chairs: Dr David Bowden and Dr Praveen Peddu</b></p>		
11:10 -11.30	<p>SABR in 2026 <b>Speaker:</b> Dr James Good</p>	
11.30-11.50	<p>SIRT in 2026 <b>Speaker:</b> Dr Peter Littler</p>	
11.50-12.10	<p>IA embolic therapy in 2026 <b>Speaker:</b> Prof Mark Calloway</p>	
12.10-12.30	<p>Histotripsy: New fad or here to stay? <b>Speaker</b> – Prof Tim Ziemlewicz - <i>Virtual</i></p>	
12.30-13.00	<p><b>Best of Abstracts – Chair – Prof Shish Shetty</b></p> <p><i>The urinary steroid metabolome can distinguish between cirrhosis and HCC and between certain aetiologies of cirrhosis.</i> <b>Speaker:</b> Hamish Miller, OCDEM, University of Oxford</p> <p>Use of Stereotactic Ablative Radiotherapy as a Locoregional Treatment Option for Hepatocellular Carcinoma – Outcomes at a Regional Centre <b>Speaker:</b> Bosire Oroko, Royal Free Hospital</p>	



*HCC-UK is supported by sponsors including pharmaceutical companies. Pharmaceutical companies have solely provided financial sponsorship, with no input into the arrangements or agenda of the meeting, except where indicated. A full list of sponsors can be found at the bottom of the agenda*

13.00-14.15	<i>Lunch – Poster viewing</i>	
<b>Session 3 – Oncology</b> <b>Chairs: Alexa Childs &amp; Dr Louise Wade</b>		
14.15-14.35	Outline of Systemic therapy for advanced stage HCC in 2026 <b>Speaker:</b> Dr Mabel Teng	
14.35-14.55	Adjuvant and neo-adjuvant Systemic therapy <b>Speaker:</b> Dr Antonio D’Alessio	
14.55-15.15	Combination of systemic therapy and loco-regional therapy <b>Speaker:</b> Prof Jeff Evans	
15.20-15.45	<i>Refreshments and Exhibition</i>	
<b>Session 4: MDT</b> <b>Host: Dr Abid Suddle</b>		
15.45-16.45	Surgeon – <b>David Wallace</b> Pathologist - <b>Dr Elizabeth Hepburn</b> Radiologist on Panel - <b>Dr David Bowden</b> IR Radiologist - <b>Prof Mark Calloway</b> Oncologist – <b>Dr Alexa Childs</b> CNS: <b>Alison Prichard</b> Dr Laura Backhouse – Bristol Dr Katharine Hutchinson Dr Dev Chatterjee	
16.45-17.00	<b>Wrap up and close</b>	

**Thank you to our Partners and Sponsors**

**Pharmaceutical companies have solely provided financial sponsorship, with no input into the arrangements or agenda of the meeting**





*HCC-UK is supported by sponsors including pharmaceutical companies. Pharmaceutical companies have solely provided financial sponsorship, with no input into the arrangements or agenda of the meeting, except where indicated. A full list of sponsors can be found at the bottom of the agenda*



Novo Nordisk has provided funding to BASL to be a Corporate Sponsor for 2026

**GOLD Sponsor**



**SILVER Sponsor**



**EXHIBITION SPONSORS**



***HCC-UK is supported by sponsors including pharmaceutical companies. Pharmaceutical companies have solely provided financial sponsorship, with no input into the arrangements or agenda of the meeting, except where indicated. A full list of sponsors can be found at the bottom of the agenda***

